Quick Answer
Greenwich LifeSciences, Inc. reported Operating Income of -$16.01 million for fiscal year 2024.
Greenwich LifeSciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$16.01M | -71.7% |
| 2023 | -$9.33M | -16.0% |
| 2022 | -$8.04M | -74.9% |
| 2021 | -$4.60M | -146.7% |
| 2020 | -$1.86M | +45.6% |
| 2019 | -$3.43M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.17M | -53.0% | -3.2% |
| June 30, 2025 | -$4.05M | -52.0% | -23.3% |
| March 31, 2025 | -$3.28M | -29.4% | -20.3% |
| September 30, 2024 | -$2.73M | -9.0% | -2.5% |
| June 30, 2024 | -$2.66M | -52.3% | -4.9% |
| March 31, 2024 | -$2.54M | -13.2% | -1.4% |
| September 30, 2023 | -$2.50M | -5.0% | -43.2% |
| June 30, 2023 | -$1.75M | -126.0% | +22.0% |
- Greenwich LifeSciences, Inc. showed a decrease of -71.7% in Operating Income compared to the prior fiscal year.
- Over the 2019–2024 period, Greenwich LifeSciences, Inc.’s operating income has declined by 367.5% (from -$3.43 million to -$16.01 million).
- The most recent figure is from Greenwich LifeSciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: